Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, announced a partnership with Rady Children’s Institute for Genomic Medicine to advance and evaluate a novel newborn screening technology to facilitate diagnosis of genetic diseases.
[Inozyme Pharma, Inc.]
